Article

Quality of Life Analysis in Patients Submitted to Dendritic Cell Vaccination for High Grade Gliomas: Update Report on a Phase II DC Trial

2025-07-17

Abstract excerpt

Measuring quality of life (QoL) in patients with high-grade central nervous system (CNS) malignancies is crucial, as these patients often endure severe physical, cognitive, and emotional challenges that significantly impact their overall well-being. Understanding and improving QoL is essential for guiding treatment strategies that not only extend survival but also enhance daily functioning and patient satisfaction...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6e9e514b-7738-5149-ae63-cc576a83396f
DOI: 10.20944/preprints202507.1471.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Quality of Life Analysis in Patients Submitted to Dendritic Cell Vaccination for High Grade Gliomas: Update Report on a Phase II DC TrialDOI 10.20944/preprints202507.1471.v1Read

Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.Semantic proximity Read

Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma PatientsSemantic proximity Read

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of GlioblastomaSemantic proximity Read

Combination of Immunotherapy and Radiotherapy for Recurrent Malignant Gliomas: Results From a Prospective Study.Semantic proximity Read

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant gliomaSemantic proximity Read

A non-randomized, open-label, dose-finding, first-in-human trial of combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: transgene expression persists up to 17 months post-vector injectionSemantic proximity Read

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade gliomaSemantic proximity Read

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Semantic proximity Read

Quality of life and outcomes of patients operated on for glioblastoma at the Yaoundé General HospitalSemantic proximity Read

Neurocognitive functioning and quality of life in patients receiving radiotherapy for intracranial meningiomas. Systematic reviewSemantic proximity Read

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.Semantic proximity Read